Business- Page 107

Webinar will be held on November 5, 2026, at 11:00 AM Eastern Time NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s

Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal enhanced potency and specificity

Proposed Acquisition Strategically Expands Eagle’s Domestic Uranium Resource Portfolio RENO, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) — Eagle Nuclear Energy Corp. (“Eagle” or the “Company”) (NASDAQ: NUCL), a next-generation nuclear energy company,

WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B Repeated Once-Daily Dosing

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care

Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives First national CNSide payer agreement to include both tumor cell enumeration and molecular profiling

Following $1.03 million in completed annualized cost reductions, Polar targets approximately $2 million in total annualized savings, inclusive of Phase 1 of its Restructuring, while positioning operations to support scalable revenue growth

– Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP, as

Third quarter net sales of $7.9 billion, an increase of 10.4% Third quarter net income of $318 million, a decrease of 1.2% Third quarter Adjusted EBITDA1 of $1.0 billion, an increase of

– Quarterly Revenue of $195.3 million – – Income from Operations of $29.0 million – – Net Income of $17.9 million – – Adjusted EBITDA1 of $39.8 million – – Backlog and